Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,188 | 21 | 70.4% |
| Honoraria | $500.00 | 1 | 29.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Medline Industries, Inc. | $500.00 | 1 | $0 (2017) |
| Janssen Biotech, Inc. | $239.57 | 2 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $227.70 | 3 | $0 (2024) |
| Amgen Inc. | $157.04 | 3 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $140.23 | 2 | $0 (2023) |
| Lilly USA, LLC | $134.49 | 2 | $0 (2022) |
| AbbVie, Inc. | $92.51 | 1 | $0 (2018) |
| Galderma Laboratories, L.P. | $82.75 | 1 | $0 (2018) |
| Arcutis Biotherapeutics, Inc. | $28.70 | 2 | $0 (2023) |
| Aroa Biosurgery Incorporated | $20.11 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $210.53 | 2 | Janssen Biotech, Inc. ($114.57) |
| 2023 | $162.19 | 10 | Amgen Inc. ($33.49) |
| 2022 | $252.40 | 3 | Lilly USA, LLC ($134.49) |
| 2021 | $137.38 | 2 | Amgen Inc. ($123.55) |
| 2019 | $249.99 | 2 | Janssen Biotech, Inc. ($125.00) |
| 2018 | $175.26 | 2 | AbbVie, Inc. ($92.51) |
| 2017 | $500.00 | 1 | Medline Industries, Inc. ($500.00) |
All Payment Transactions
22 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 02/23/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $95.96 | General |
| Category: ONCOLOGY | ||||||
| 01/11/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $114.57 | General |
| Category: Immunology | ||||||
| 12/13/2023 | PFIZER INC. | EUCRISA (Drug), CIBINQO, LITFULO | Food and Beverage | In-kind items and services | $14.78 | General |
| Category: DERMATOLOGY | ||||||
| 10/24/2023 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $15.95 | General |
| Category: Inflammation | ||||||
| 10/03/2023 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $14.19 | General |
| Category: Immunology | ||||||
| 09/28/2023 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $19.43 | General |
| Category: Immunology | ||||||
| 09/21/2023 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $15.24 | General |
| Category: Dermatology | ||||||
| 09/07/2023 | Arcutis Biotherapeutics, Inc. | — | Food and Beverage | In-kind items and services | $14.17 | General |
| 05/10/2023 | Aroa Biosurgery Incorporated | — | Food and Beverage | Cash or cash equivalent | $20.11 | General |
| 03/14/2023 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $17.54 | General |
| Category: Inflammation | ||||||
| 03/07/2023 | Arcutis Biotherapeutics, Inc. | — | Food and Beverage | In-kind items and services | $14.53 | General |
| 02/07/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | SPEVIGO (Drug) | Food and Beverage | In-kind items and services | $16.25 | General |
| Category: IMMUNOLOGY | ||||||
| 10/28/2022 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $117.91 | General |
| Category: ONCOLOGY | ||||||
| 09/21/2022 | Lilly USA, LLC | TALTZ (Drug) | Food and Beverage | Cash or cash equivalent | $120.03 | General |
| Category: Immunology | ||||||
| 05/12/2022 | Lilly USA, LLC | TALTZ (Drug) | Food and Beverage | In-kind items and services | $14.46 | General |
| Category: Immunology | ||||||
| 12/09/2021 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $123.55 | General |
| Category: Inflammation | ||||||
| 04/08/2021 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $13.83 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 10/23/2019 | Novartis Pharmaceuticals Corporation | COSENTYX (Biological) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: DERMATOLOGY | ||||||
| 03/01/2019 | Janssen Biotech, Inc. | Tremfya (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Immunology | ||||||
| 05/06/2018 | Galderma Laboratories, L.P. | EPIDUO FORTE (Drug) | Food and Beverage | In-kind items and services | $82.75 | General |
| Category: ACNE | ||||||
| 01/11/2018 | AbbVie, Inc. | — | Food and Beverage | In-kind items and services | $92.51 | General |
| 12/08/2017 | Medline Industries, Inc. | — | Honoraria | Cash or cash equivalent | $500.00 | General |
| Category: Dermatology and Wound Care | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 307 | 481 | $90,786 | $34,633 |
| 2022 | 8 | 271 | 428 | $49,754 | $34,999 |
| 2021 | 4 | 217 | 304 | $49,515 | $24,230 |
| 2020 | 9 | 388 | 571 | $49,338 | $31,160 |
All Medicare Procedures & Services
31 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 124 | 233 | $46,073 | $17,794 | 38.6% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 50 | 78 | $9,748 | $3,899 | 40.0% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 33 | 33 | $8,093 | $3,037 | 37.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 20 | 25 | $6,974 | $2,558 | 36.7% |
| 10040 | Acne surgery | Office | 2023 | 15 | 21 | $5,557 | $2,180 | 39.2% |
| 11301 | Shaving of skin growth of body, arms, or legs, 0.6-1.0 cm | Office | 2023 | 12 | 14 | $3,903 | $1,456 | 37.3% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 18 | 19 | $4,420 | $1,449 | 32.8% |
| 11310 | Shaving of skin growth of face, ears, eyelids, nose, lips, or mouth, 0.5 cm or less | Office | 2023 | 11 | 11 | $2,938 | $1,127 | 38.4% |
| 11900 | Injection into skin growth, 1-7 growths | Office | 2023 | 12 | 23 | $2,964 | $1,113 | 37.6% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 12 | 24 | $115.54 | $19.98 | 17.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 126 | 261 | $27,484 | $20,024 | 72.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 28 | 44 | $6,648 | $4,836 | 72.8% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 36 | 36 | $4,906 | $3,200 | 65.2% |
| 11301 | Shaving of skin growth of body, arms, or legs, 0.6-1.0 cm | Office | 2022 | 16 | 16 | $2,713 | $1,494 | 55.1% |
| 11310 | Shaving of skin growth of face, ears, eyelids, nose, lips, or mouth, 0.5 cm or less | Office | 2022 | 15 | 16 | $2,239 | $1,484 | 66.3% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 26 | 31 | $2,105 | $1,482 | 70.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 11 | 11 | $2,066 | $1,411 | 68.3% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 13 | 13 | $1,593 | $1,067 | 67.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 104 | 177 | $27,568 | $14,030 | 50.9% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 46 | 46 | $10,963 | $4,293 | 39.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 25 | 32 | $7,014 | $3,674 | 52.4% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 42 | 49 | $3,970 | $2,233 | 56.2% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 104 | 158 | $14,730 | $9,187 | 62.4% |
| 99212 | Established patient office or other outpatient visit, typically 10 minutes | Office | 2020 | 111 | 215 | $12,164 | $7,601 | 62.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 66 | 67 | $8,917 | $5,474 | 61.4% |
About Dr. Gary Brauner, MD
Dr. Gary Brauner, MD is a Procedural Dermatology healthcare provider based in Cresskill, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/24/2006. The National Provider Identifier (NPI) number assigned to this provider is 1730149501.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gary Brauner, MD has received a total of $1,688 in payments from pharmaceutical and medical device companies, with $210.53 received in 2024. These payments were reported across 22 transactions from 14 companies. The most common payment nature is "Food and Beverage" ($1,188).
As a Medicare-enrolled provider, Brauner has provided services to 1,183 Medicare beneficiaries, totaling 1,784 services with total Medicare billing of $125,022. Data is available for 4 years (2020–2023), covering 31 distinct procedure/service records.
Practice Information
- Specialty Procedural Dermatology
- Other Specialties Procedural Dermatology, Dermatology
- Location Cresskill, NJ
- Active Since 03/24/2006
- Last Updated 05/09/2025
- Taxonomy Code 207NS0135X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1730149501
Products in Payments
- LIBTAYO (Biological) $213.87
- Otezla (Drug) $157.04
- TALTZ (Drug) $134.49
- Tremfya (Drug) $125.00
- COSENTYX (Biological) $124.99
- TREMFYA (Drug) $114.57
- EPIDUO FORTE (Drug) $82.75
- DUPIXENT (Biological) $33.26
- SPEVIGO (Drug) $16.25
- COSENTYX (Drug) $15.24
- EUCRISA (Drug) $14.78
- Sotyktu (Drug) $14.19
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.